Glucose intolerance in uremia (A- and B-cell function during conservative and dialytic management. 1977

M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti

Glucose tolerance and insulin and glucagon secretion were investigated in two groups of uremic patients, respectively on conservative and hemodialytic treatment. For this purpose, a glucose infusion was performed in the fasting state. Glucose intolerance was observed in uremic patients; hemodialysis improved, but did not normalize the glucose disposal. In uremic patients both on conservative and dialytic treatment plasma insulin and glucagon levels were higher than in the control group; the pattern of glucagon suppression was well maintained. The data obtained suggest that glucose intolerance in uremia is related mainly to peripheral insulin resistance and is not due to hyperglucagonemia.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
April 1989, Nihon Ika Daigaku zasshi,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
January 1975, Minerva nefrologica,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
December 1978, Metabolism: clinical and experimental,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
July 1980, The American journal of clinical nutrition,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
December 1983, Annals of internal medicine,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
December 1983, Kidney international. Supplement,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
August 1978, The Journal of clinical investigation,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
February 2001, Kidney international. Supplement,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
January 1981, Metabolic bone disease & related research,
M M Benedetti, and F Santeusanio, and G Angeletti, and P Filipponi, and U Buoncristiani, and P Brunetti
January 2020, Current opinion in nephrology and hypertension,
Copied contents to your clipboard!